Vaxxinity, Inc. Class A Common Stock
VAXX
VAXX was delisted on the 8th of May, 2024.
48 hedge funds and large institutions have $18.9M invested in Vaxxinity, Inc. Class A Common Stock in 2023 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 13 increasing their positions, 2 reducing their positions, and 3 closing their positions.
600% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 3
550% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 2
149% more capital invested
Capital invested by funds: $7.6M → $18.9M (+$11.3M)
60% more funds holding
Funds holding: 30 → 48 (+18)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$5.07M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$771K |
| 3 |
Millennium Management
New York
|
+$428K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$318K |
| 5 |
Goldman Sachs
New York
|
+$242K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$610K |
| 2 |
Renaissance Technologies
New York
|
-$151K |
| 3 |
Lido Advisors
Los Angeles,
California
|
-$19.4K |
| 4 |
VF
Virtu Financial
New York
|
-$14.1K |
| 5 |
NA
NewEdge Advisors
New Orleans,
Louisiana
|
-$4 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$525 | +207 | New |
|
VAXX Hedge Fund Activity: Q1 2023 in Review
48 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Vaxxinity, Inc. Class A Common Stock (VAXX) for Q1 2023, worth a combined $18.9M — up 149% from $7.6M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new VAXX positions and 3 closed out — a net gain of 18 holders — while 13 added to existing stakes and 2 trimmed.
The largest buyer was Adage Capital Partners, adding an estimated $5.07M. The largest seller was Bank of America, cutting an estimated $610K.
- 48 institutional investors held Vaxxinity, Inc. Class A Common Stock (VAXX) as of Q1 2023, up from 30 in Q4 2022.
- Funds reported $18.9M of Vaxxinity, Inc. Class A Common Stock stock for Q1 2023, up 149% quarter-over-quarter.
- 21 funds opened new Vaxxinity, Inc. Class A Common Stock positions in Q1 2023 and 3 closed out, a net change of +18 holders.
- The largest Vaxxinity, Inc. Class A Common Stock buyer in Q1 2023 was Adage Capital Partners, an estimated $5.07M added.
- The largest Vaxxinity, Inc. Class A Common Stock seller in Q1 2023 was Bank of America, an estimated $610K sold.
Based on aggregated 13F filings for Q1 2023.